Overview: PAI-1 inhibitors and clinical applications
Plasminogen activator inhibitor-1 (PAI-1) is a protein involved in the fibrinolytic system and has been reported to be involved in various pathologies such as fibrosis and inflammation. We have developed small molecule inhibitors of human PAI-1 for clinical applications. A clinical candidate compound (TM5509) was finally identified among over 1400 derivatives of a hit compound (TM5275) searched by the X-ray crystal structure information of human PAI-1 and the in silico approach on a big virtual chemical library. From pre-clinical studies using our PAI-1 inhibitors, new therapeutic concepts for clinical applications, such as anti-cancer and anti-aging, have been conceived, some oh which have been tested in various investigator-initiated clinical trials.
Authors
- Toshio Miyata (ORCID: https://orcid.org/0000-0001-9153-5024)
Institutions
- Toho University (JP)
- Tohoku University (JP)
Publication Details
- Journal
- Biomedical Journal
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1016/j.bj.2025.100874
- Citations
- 4
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 3.75